Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of AVANZ Salsola Immunotherapy
NCT02065856Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Dec 2013
- Primary completion
- Aug 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Avanz Salsola kali in allergic rhinoconjunctivitis (ARC), sponsored by ALK-Abelló. Started Dec 2013; status: completed.
02
Drugs
Avanz Salsola kali
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02065856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065856.